360 related articles for article (PubMed ID: 38558819)
1. The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.
Maurer K; Antin JH
Front Immunol; 2024; 15():1328858. PubMed ID: 38558819
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.
Burt RK; Drobyski WR; Seregina T; Traynor A; Oyama Y; Keever-Taylor C; Stefka J; Kuzel TM; Brush M; Rodriquez J; Burns W; Tennant L; Link C
Exp Hematol; 2003 Oct; 31(10):903-10. PubMed ID: 14550806
[TBL] [Abstract][Full Text] [Related]
4. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
5. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.
Chang X; Zang X; Xia CQ
Bone Marrow Transplant; 2016 Mar; 51(3):324-32. PubMed ID: 26595077
[TBL] [Abstract][Full Text] [Related]
6. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
Ho VT; Kim HT; Kao G; Cutler C; Levine J; Rosenblatt J; Joyce R; Antin JH; Soiffer RJ; Ritz J; Avigan D; Alyea EP
Am J Hematol; 2014 Dec; 89(12):1092-6. PubMed ID: 25132538
[TBL] [Abstract][Full Text] [Related]
7. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation.
Leis J; Porter DL
Leuk Lymphoma; 2002 Jan; 43(1):9-17. PubMed ID: 11908741
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
12. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934
[TBL] [Abstract][Full Text] [Related]
13. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
14. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
15. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
Luznik L; Fuchs EJ
Cancer Control; 2002; 9(2):123-37. PubMed ID: 11965233
[TBL] [Abstract][Full Text] [Related]
16. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
[TBL] [Abstract][Full Text] [Related]
18. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
Front Immunol; 2019; 10():1542. PubMed ID: 31354710
[TBL] [Abstract][Full Text] [Related]
19. Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter.
Ros-Soto J; Snowden JA; Szydlo R; Nicholson E; Madrigal A; Easdale S; Potter M; Ethell M; Anthias C
Transplant Cell Ther; 2022 Apr; 28(4):183.e1-183.e8. PubMed ID: 35104660
[TBL] [Abstract][Full Text] [Related]
20. A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
Lu N; Lin J; Wang LL; Li YY; Wang LJ; Gao CJ; Liu DH; Gao XN
Int J Hematol; 2022 May; 115(5):713-727. PubMed ID: 35128587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]